Bayer/Ionis Advance Next-Generation Antithrombotic After Positive Clinical Results
And Bayer Sets Up Artificial Intelligence Center In The UK
In a collaboration with Ionis Pharmaceuticals, Bayer is pressing ahead with Phase II clinical studies of an antisense molecule designed to reduce Factor XI production and prevent thrombosis.
You may also be interested in...
The Leverkusen-based firm has been touting the potential of its pharmaceutical pipeline which it hopes will be able to help soften the blow of patent expiries on the blockbusters Xarelto and Eylea in the next few years.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
The UK-based group will help Bayer accelerate clinical development of new treatments for cardiovascular disease using Sensyne Health’s clinical AI technology platform and NHS data.